Highly purified eicosapentaenoic acid, as free fatty acid for treatment of coronaviruses and specifically novel coronavirus-19 (covid-19)
AssigneesS.L.A. Pharma AG, KD Swiss GmbH
InventorsAndrea BELLUZZI, Roger James LEICESTER
Life of this patent
Estimating the term…
Abstract
This present invention relates to the use of eicosapentaenoic acid (EPA) for treating and reducing the negative effects of respiratory virus including coronaviruses and particularly the novel coronavirus-19 (COVID-19). Notably, the eicosapentaenoic acid in the free fatty acid (EPA-FFA) form has a purity of at least has a purity of at least 90%, preferably 95% and more preferably at least 99%. Specifically, the EPA-FFA exhibits a reduction of expressed interleukins, such as IL-6, reduction in D-dimers and a reduction relating to the release of AA.
Claims9
A method for treating and reducing the effects of COVID-19 and variants thereof in a subject, the method comprising administering to the subject a therapeutic amount of eicosapentaenoic acid in the free fatty acid (EPA-FFA) form having purity of at least 95%.
A method for alleviating the cytopathic destructive effects of COVID-19 and variants thereof in a human patient infected with such a virus comprising administering to said patient a therapeutically-effective amount of EPA-FFA having a purity of at least has a purity of at least 90%, preferably 95% and more preferably at least 99% or a composition containing such a compound.
A method to modulate an immune response caused by increase in the expression of interleukins and the release of arachidonic acid (AA), the method comprising the administration to a subject a therapeutically effective amount of EPA-FFA having a purity of 99% to reduce the level of interleukins and release of AA.
A method to reduce a late complication event of COVE) 19 and variants thereof, wherein the late complication is lung fibrosis in a subject, wherein EPA-FFA is SLA-40515.252 administered in an amount to reduce IL-6 and VEGF production and the secondary neo angiogenesis that ultimately generates pulmonary fibrosis.
9-10. (canceled)
Dependencies are inferred from the claim text.